Navigation Links
Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study
Date:5/12/2009

CALGARY, May 12 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY) is pleased to announce today that it has successfully completed patient enrolment in its multi-centre Phase 2 clinical trial to evaluate the intravenous administration of REOLYSIN(R) in patients with various sarcomas that have metastasized to the lung. A total of 52 patients have been enrolled in the trial.

"We are extremely pleased to have had the opportunity to participate in this study," said Dr. Monica Mita, principal investigator at the Institute of Drug Development (IDD), the Cancer Therapy & Research Center at the University of Texas Health Science Center, (UTHSC), San Antonio, Texas.

"REOLYSIN is very well tolerated and a number of patients have derived clinical benefit. Based on the study results, which will be updated and presented at ASCO this year, further studies are planned in patients with sarcoma."

The primary statistical endpoint of the trial was met in late 2008. To meet the endpoint, at least three out of 52 patients had to experience stabilization of disease or better for more than six months. Of the 33 patients evaluable at that time, five had experienced stable disease for periods greater than six months, including one patient who had maintained stable disease for more than 16 months. An additional 10 patients had experienced stable disease for periods ranging from three to six cycles (cycle = 28 days). Updated results are scheduled to be presented May 30, 2009 at the American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Florida.

Clinical Trial Design

The trial (REO 014) is a Phase 2, open-label, single agent study whose primary objective is to measure tumour responses and duration of response, and to describe any evidence of antitumour activity of intravenous, multiple dose REOLYSIN in patients with bone and soft tissue sarcomas metastatic to the lung. REOLYSIN is delivered intravenously to patients at a dose of 3x1010 TCID50 for five consecutive days, every 28 days.

Eligible patients had to have a bone or soft tissue sarcoma metastatic to the lung deemed by their physician to be unresponsive to or untreatable by standard therapies. These included patients with osteosarcoma, Ewing sarcoma family tumours, malignant fibrous histiocytoma, synovial sarcoma, fibrosarcoma and leiomyosarcoma.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN, its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolyticsbiotech.com

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the U.S. Phase II sarcoma clinical trial and the Company's belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the tolerability of REOLYSIN outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
2. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
3. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
4. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
5. Finkelstein Thompson LLP Announces GPC Biotech AG Investigation
6. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
7. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
8. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
9. Shareholder Class Action Filed Against GPC Biotech AG by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
10. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
11. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... (PRWEB) , ... April 25, 2017 , ... LABS, Inc. ... were added to its extensive test menu: Nucleic Acid Testing (NAT) for ZIKV; ... LABS was only able to offer NAT screening for blood donors under an Investigational ...
(Date:4/26/2017)... ... April 26, 2017 , ... NextSteps ... and North America this May on the following dates: , ?    London, ... Taylor, Chairman of the Learning and Performance Institute will be the opening ...
(Date:4/26/2017)... April 26, 2017  Genisphere LLC, provider of ... signed a collaborative and sponsored research agreement with ... Muro . The overall goal of the partnership ... various 3DNA designs and formulations after in ... of the vasculature as well as inflammatory responses, ...
(Date:4/25/2017)... Oakland, California (PRWEB) , ... April 25, 2017 ... ... Artificial Intelligence (AI), leading supplier of Common Lisp (CL) development tools, and market ... 10.1 , which includes key performance enhancements now available within the most effective ...
Breaking Biology Technology:
(Date:3/20/2017)... March 20, 2017 At this year,s CeBIT Chancellor ... biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG stand together with ... this year,s CeBIT partner country. At the largest German biometrics company the ... fingerprint, face and iris recognition as well as DERMALOGĀ“s multi-biometrics system.   ... ...
(Date:3/16/2017)... 16, 2017 CeBIT 2017 - Against identity fraud with DERMALOG solutions ... ... Used combined in one project, multi-biometric solutions provide a crucial contribution against ... Used combined in one project, ... ...
(Date:3/9/2017)... March 9, 2017 4Dx has publicly released ... Imaging Workshop at the University of Pennsylvania. Founder and ... deliver the latest data to world leaders in lung ... together leaders at the forefront of the industry to ... "The quality of the imaging is ...
Breaking Biology News(10 mins):